Grifols, S.A. (GRFS)
InfravaloradaFundamental
76
Precio
$7.30
Capitalización Bursátil
$4.98B
Parte 1 · Cuánto vale la empresa
Resumen
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
A smaller US fractionator with its own donation centers whose immunoglobulin Asceniv competes for the same immunodeficiency patients and the same US plasma donors.
Its non-plasma antibody Vyvgart treats myasthenia gravis and CIDP, the neurological indications that account for a large share of Grifols' immunoglobulin revenue.
The largest plasma fractionator worldwide, it collects donor plasma in the same US centers and sells rival immunoglobulins and the alpha-1 therapy Respreeza against Grifols' Gamunex and Prolastin.
Through its BioLife donation network and its plasma-derived business, it sells a 10% liquid immunoglobulin and the alpha-1 products Aralast and Glassia to the same hospitals and specialty pharmacies Grifols supplies.
A privately held Swiss fractionator that runs its own US plasma centers and markets 5% and 10% liquid immunoglobulins competing head-on with Flebogamma and Xembify.
An Italian private plasma company selling immunoglobulins, albumin and hyperimmunes in Europe and the United States, the same product range and the same territories as Grifols' Biopharma division.
Balance y Liquidez
Ingresos
$2.01B
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Beneficio Neto
$172M
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Flujo de Caja Libre
$573M
Patrimonio Neto Total
$1.20B
Pasivo Total
$9.36B
Ratio de Liquidez
2.37
Cobertura de Intereses
-
Deuda/EBITDA
5.69
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$12.35
Precio Actual
$7.30
Margen de Seguridad
+40.9%
Rango de Valor Justo
$8.03 - $16.67
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
10.99
ROE
6.9%
Ratio P/B
0.90
P/FCF
3.29
Margen Bruto
37.0%
ROIC
8.8%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
8.8%
WACC
3.6%
ROIC − WACC
+5.2 pp
El ROIC supera el coste del capital: la empresa está creando valor para los accionistas.
Criterios de Análisis Fundamental
Superado (16)
- ROIC 8.8%
- Gross Margin 37.0%
- P/FCF 3.29
- P/B Ratio 0.90
- Operating Margin 16.2%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Undervalued)
- ROE 8.4%
- Revenue Growth 5Y 7.1%
- Analyst Consensus 67% Buy
- Earnings Surprise avg 45.6%
- Earnings Quality (OCF/NI) 2.71
- Net Margin Trend 5.3% vs 2.2%
Fallido (4)
- Price CAGR -7.72%
- Debt/Equity ratio
- CapEx intensity
- Piotroski F-Score 2/9
No disponible (7)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Jose Ignacio Abia Buenache | CEO & Director | 57 |
| Mr. Rahul Srinivasan | Chief Financial Officer | 48 |
| Mr. Lluis Pons Gomez | Senior Vice President of Strategy & COO Office | 41 |
| Daniel Segarra | Head of Investor Relations & Sustainability and Vice President | - |
| Mr. David Ian Bell | Chief Corporate Affairs & Legal Officer | 71 |
| Mr. Enrique de la Torre | Chief Compliance Officer | 52 |
| Ms. Montse Ribas | Chief Communications and Reputation Officer | 56 |
| Mr. Camille Alpi | Chief Human Resources & Talent Officer | 44 |
| Mr. Vicente Blanquer Torre | Chief Quality Officer | 64 |
| Mr. Ignacio Ramal Subira | Chief Internal Audit & Enterprise Risk Manager | 57 |
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for GRFS, sourced from Markets Gazette.